SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending after reports surfaced of a potential partnership with Novo Nordisk to distribute GLP-1 obesity drugs, signaling an end to their prior legal dispute. This development has ignited fervent community discussion about a massive short squeeze due to the stock's high short interest and its strengthened position in the digital health market.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community celebrates the imminent departure of a prominent FDA official, widely seen as a significant barrier to the approval of its Duchenne Muscular Dystrophy therapy, Deramiocel. This development, coupled with high anticipation for a late-breaking Phase 3 data presentation at a major medical conference, is fueling intense bullish sentiment and expectations for a rapid regulatory decision.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending after forming a partnership with Hims & Hers to distribute its obesity drugs, ending a prior feud and surprising the community. This, alongside reports of rapidly accelerating oral Wegovy prescriptions and an FDA crackdown on compounded GLP-1s, is driving discussion that the stock is oversold despite ongoing competitive dynamics with Eli Lilly.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure NV is surging on high volume as the community speculates a massive short squeeze and a bullish sentiment shift, following news of a key FDA official's impending departure, which is seen as favorable for gene therapies like QURE's Huntington's therapy. This is amplified by discussions of a newly clarified, less burdensome regulatory path for their lead asset and a technical rebound from oversold conditions.

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Savara Inc

Savara is trending following the FDA's Day 74 Letter confirming MOLBREEVI's Biologics License Application is under full review with a PDUFA target action date of August 22, 2026, and no advisory committee meeting planned. The community sees this as a positive step towards Molbreevi becoming a first-in-class therapy for autoimmune PAP, fueling optimism around its market potential and future valuation.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is trending as escalating U.S.-Iran tensions have severely disrupted oil tanker traffic through the Strait of Hormuz, propelling crude prices higher. The community is split between calls for further parabolic gains to $150-$200 due to broken supply chains and warnings of a manipulated "blow-off top" and imminent correction, with broader concerns about inflation.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

VOO is trending amidst heightened market uncertainty driven by Federal Reserve policy, geopolitical developments, and ongoing debates about the sustainability of valuations in the tech sector. Despite some community calls for a significant correction, many investors continue to favor VOO for its broad market exposure and long-term stability.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

SOXX is driving intense conversation, fueled by fresh reports of potential Nvidia chip exports to China and strong AI demand outlooks from semiconductor giants, though community sentiment is sharply divided. While many view the sector as an unstoppable "infinite money glitch" in the AI boom, others warn of an impending "bubble" due to stretched valuations and recent underperformance against software ETFs.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is trending as its inclusion in the S&P 500 and a significant investment from NVIDIA for optical technology in AI infrastructure drive conversation, fueling an active debate among investors regarding its current valuation and the future adoption of photonics versus copper solutions.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as its CEO hints at "curative outcomes" for AML, sparking community excitement about groundbreaking efficacy and a potential short squeeze, with further anticipation from an ongoing oncology summit. The prolonged duration of its pivotal REGAL trial, indicating patients are living longer than expected, reinforces investor belief in the drug's transformative potential beyond disease management.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?

KROS advances rinvatercept for Duchenne muscular dystrophy, with a phase II trial planned for 2026 after gaining FDA orphan drug designation.

Royce & Associates LP Has $2.01 Million Holdings in PTC Therapeutics, Inc. $PTCT

Royce & Associates LP lessened its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 34.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange...

Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing

Key PointsAdded 41,303 shares of PTC Therapeutics; estimated trade size $3.00 million based on quarterly average pricing...

Oversold Conditions For PTC Therapeutics (PTCT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...

JPMorgan Chase & Co. Reduces Holdings in PTC Therapeutics, Inc. $PTCT

JPMorgan Chase & Co. lowered its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 18.4% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund...

GSA Capital Partners LLP Decreases Position in PTC Therapeutics, Inc. $PTCT

GSA Capital Partners LLP trimmed its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 82.8% during the 3rd quarter, according to the company in its most recent filing with the...

PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the sixteen brokerages that are presently covering the company...

PTC Therapeutics, Inc. $PTCT Holdings Decreased by Vanguard Group Inc.

Vanguard Group Inc. lessened its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 6.3% in the third quarter, according to its most recent filing with the Securities & Exchange...

16,062 Shares in PTC Therapeutics, Inc. $PTCT Purchased by Private Capital Advisors Inc.

Private Capital Advisors Inc. acquired a new position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and...

PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 3,019 Shares

PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) VP Mark Elliott Boulding sold 3,019 shares of the business's stock in a transaction on Thursday, February 19th. The stock was sold at an average...

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

PTCT
PTC Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PTCT News

PTCTPTC Therapeutics Inc